Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients

被引:2
作者
Aladdin, H
Larsen, CS
Schjerling, P
Moller, BK
Buhl, MR
Gerstoft, J
Pedersen, BK
Ullum, H
机构
[1] Rigshosp, Dept Infect Dis, DK-2200 Copenhagen N, Denmark
[2] Rigshosp, Copenhagen Muscle Res Ctr, DK-2200 Copenhagen N, Denmark
[3] Rigshosp, Dept Clin Immunol, DK-2200 Copenhagen N, Denmark
[4] Marselisborg Hosp, Dept Med & Infect Dis, Aarhus, Denmark
关键词
D O I
10.1046/j.1365-3083.2001.00876.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In this study we investigated the effect of interleukin-2 (IL-2) on mean terminal restriction fragment (TRF) lengths in peripheral blood mononuclear cells (PBMC). Ten human immunodeficiency virus (HIV)-infected individuals were included and IL-2 was administered subcutaneously with 3 x 10(6) IU three times a week for 24 weeks. Mean TRF length was decreased on average by 267 bp at week 4 (P = 0.03) and 286 bp at week 8 (P = 0.09). Individual TRF changes at weeks 12, 16, 20 and 24 were highly variable. However, in the 12 weeks following therapy, TRF lengths generally increased reaching baseline levels by the end of the study. At baseline, mean TRF lengths were positively correlated to the ratio of naive and memory phenotype within both CD4(+) and CD8(+) cells. This study shows that IL-2 treatment induces transient shortened mean TRF lengths in PBMC from HIV-infected individuals, indicating that IL-2 enhances the lymphocyte count by peripheral proliferation or recruitment of memory T cells into the blood.
引用
收藏
页码:315 / 319
页数:5
相关论文
共 33 条
[1]   Granulocyte colony-stimulating factor increases CD4+ T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy:: Results from a randomized, placebo-controlled trial [J].
Aladdin, H ;
Ullum, H ;
Nielsen, SD ;
Espersen, C ;
Mathiesen, L ;
Katzenstein, TL ;
Gerstoft, J ;
Skinhoj, P ;
Pedersen, BK .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :1148-1152
[2]  
Aladdin H, 2000, SCAND J IMMUNOL, V51, P168
[3]   TELOMERE LENGTH PREDICTS REPLICATIVE CAPACITY OF HUMAN FIBROBLASTS [J].
ALLSOPP, RC ;
VAZIRI, H ;
PATTERSON, C ;
GOLDSTEIN, S ;
YOUNGLAI, EV ;
FUTCHER, AB ;
GREIDER, CW ;
HARLEY, CB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (21) :10114-10118
[4]   Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4 T cells and undetectable plasma virus load [J].
Arnó, A ;
Ruiz, L ;
Juan, M ;
Jou, A ;
Balagué, M ;
Zayat, MK ;
Marfil, S ;
Martínez-Picado, J ;
Martínez, MA ;
Romeu, J ;
Pujol-Borrell, R ;
Lane, C ;
Clotet, B .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) :56-60
[5]   STRUCTURE AND FUNCTION OF TELOMERES [J].
BLACKBURN, EH .
NATURE, 1991, 350 (6319) :569-573
[6]   Mechanism of telomerase induction during T cell activation [J].
Bodnar, AG ;
Kim, NW ;
Effros, RB ;
Chiu, CP .
EXPERIMENTAL CELL RESEARCH, 1996, 228 (01) :58-64
[7]   Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :78-86
[8]   Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study [J].
Carr, A ;
Emery, S ;
Lloyd, A ;
Hoy, J ;
Garsia, R ;
French, M ;
Stewart, G ;
Fyfe, G ;
Cooper, DA .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (04) :992-999
[9]  
Davey RT, 1999, J INFECT DIS, V179, P849, DOI 10.1086/314678
[10]   Shortened telomeres in the expanded CD28- CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis [J].
Effros, RB ;
Allsopp, R ;
Chiu, CP ;
Hausner, MA ;
Hirji, K ;
Wang, LL ;
Harley, CB ;
Villeponteau, B ;
West, MD ;
Giorgi, JV .
AIDS, 1996, 10 (08) :F17-F22